# A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

> **NCT04447755** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 127 (actual)

## Conditions studied

- Relapsed or Refractory Solid Tumors

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT04447755
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-30
- **Primary completion:** 2022-09-16
- **Final completion:** 2025-02-13
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447755, "A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04447755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*